Lycia Therapeutics raised an oversubscribed $75M Series D to advance its LYTAC platform and pipeline, reinforcing investor confidence in extracellular protein degradation.
Lycia’s mission is to improve patients’ lives by stopping disease at its source. At the root of many diseases are dysregulated proteins that circulate in blood or are attached to the outside of the cell. Our novel platform addresses this issue and builds on research that revealed a new class of therapeutics – LYTAC degraders. While our initial focus is on developing therapeutics that target and eliminate the drivers of autoimmune and inflammatory diseases, our technology can target many proteins that have been well validated as drivers of disease. With our novel LYTAC degraders, we believe we can have a life-changing impact on patients who urgently need new options.